Silo Pharma Stock (NASDAQ:SILO)
Previous Close
$1.05
52W Range
$0.84 - $4.50
50D Avg
$1.13
200D Avg
$1.52
Market Cap
$4.75M
Avg Vol (3M)
$220.87K
Beta
1.39
Div Yield
-
SILO Company Profile
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
SILO Performance
Peer Comparison
Ticker | Company |
---|---|
IVA | Inventiva S.A. |
DAWN | Day One Biopharmaceuticals, Inc. |
IPSC | Century Therapeutics, Inc. |
HOOK | HOOKIPA Pharma Inc. |
CSBR | Champions Oncology, Inc. |
TERN | Terns Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
RZLT | Rezolute, Inc. |
INDP | Indaptus Therapeutics, Inc. |
TPST | Tempest Therapeutics, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
URGN | UroGen Pharma Ltd. |
BCDA | BioCardia, Inc. |
PRDS | Pardes Biosciences, Inc. |
FBRX | Forte Biosciences, Inc. |
STTK | Shattuck Labs, Inc. |
LUMO | Lumos Pharma, Inc. |
ELYM | Eliem Therapeutics, Inc. |